TSX lower after index logs fresh record closing high
DUBLIN - Investment firm Citadel Group has disclosed a 1.73% stake in Mural Oncology plc, according to a regulatory filing published Wednesday.
The filing, made under Irish Takeover Panel rules, reveals that Citadel held 300,761 shares representing a 1.73% interest in the biopharmaceutical company as of September 9, 2025. This includes 272,761 owned and controlled shares, along with stock-settled derivatives accounting for an additional 28,000 shares.
The disclosure also shows Citadel maintains short positions equivalent to 1.25% of Mural Oncology’s shares, primarily through stock-settled derivatives including options.
The filing details several transactions conducted on September 9, including multiple purchases of Mural shares at prices ranging from $2.07 to $2.08 per share. The largest single purchase involved 5,100 shares acquired at $2.0750 per share.
Citadel’s options positions include purchased call options for 14,600 shares with a $5.00 strike price expiring September 19, 2025, and various put options with strike prices primarily at $2.50.
The disclosure was made in compliance with Rule 8.3 of the Irish Takeover Panel Act, which requires public disclosure when a party holds interests in relevant securities representing 1% or more of a company that may be involved in a takeover situation.
Mural Oncology is listed on the Irish Stock Exchange with shares trading at approximately $2.07-$2.08 based on the transaction prices reported in the filing.
The information was disclosed through a regulatory filing submitted to the Irish Takeover Panel.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.